- Price
- 10.75
- Open
- —
- High
- —
- Low
- —
- Volume
- 25
- Currency
- GBX
- Market cap
- £46m
- Shares in issue
- 431,373,146
Delayed data · Source: Aquis Stock Exchange
| 30 Oct 2026 | 07:00:04 | Leading industry figure appointed chair |
| 1 Oct 2026 | 07:00:04 | Investor Presentation Via Investor Meet Company |
| 28 Sept 2026 | 15:00:00 | Result of AGM |
| 17 Sept 2026 | 07:00:02 | Employee health contract with Arnold Clark Group |
| 4 Sept 2026 | 17:05:59 | Director/PDMR shareholdings in the Company |
EDX Medical Group Plc develops and commercializes diagnostic tests focused on oncology, cardiology, and infectious diseases. The company offers a range of products, including molecular profiling tests for cancer, point-of-care devices, and advanced screening solutions. EDX Medical operates primarily in the UK and collaborates with partners like Caris Life Sciences and Thermo Fisher Scientific to enhance its diagnostic offerings. Its customers include healthcare professionals and organizations seeking to improve patient outcomes through personalized treatment and rapid disease detection.
| 30 Oct 2026 | 07:00:04 | Leading industry figure appointed chair |
| 1 Oct 2026 | 07:00:04 | Investor Presentation Via Investor Meet Company |
| 28 Sept 2026 | 15:00:00 | Result of AGM |
| 17 Sept 2026 | 07:00:02 | Employee health contract with Arnold Clark Group |
| 4 Sept 2026 | 17:05:59 | Director/PDMR shareholdings in the Company |
EDX Medical Group Plc develops and commercializes diagnostic tests focused on oncology, cardiology, and infectious diseases. The company offers a range of products, including molecular profiling tests for cancer, point-of-care devices, and advanced screening solutions. EDX Medical operates primarily in the UK and collaborates with partners like Caris Life Sciences and Thermo Fisher Scientific to enhance its diagnostic offerings. Its customers include healthcare professionals and organizations seeking to improve patient outcomes through personalized treatment and rapid disease detection.